Skip to main content
Howard Bailey, MD, Oncology, Madison, WI, University Hospital

HowardHBaileyMD

Oncology Madison, WI

Professor, Medicine, University of Wisconsin Medical School

Dr. Bailey is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Bailey's full profile

Already have an account?

Education & Training

  • University of Wisconsin Hospitals and Clinics
    University of Wisconsin Hospitals and ClinicsFellowship, Medical Oncology, 1988 - 1992
  • Western Michigan University Homer Stryker MD School of Medicine
    Western Michigan University Homer Stryker MD School of MedicineResidency, Internal Medicine, 1985 - 1988
  • University of North Dakota School of Medicine and Health Sciences
    University of North Dakota School of Medicine and Health SciencesClass of 1985

Certifications & Licensure

  • WI State Medical License
    WI State Medical License 1988 - 2025
  • IL State Medical License
    IL State Medical License 1996 - 2014
  • MI State Medical License
    MI State Medical License 1986 - 1990
  • American Board of Internal Medicine Internal Medicine

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011

Clinical Trials

Publications & Presentations

PubMed

Press Mentions

  • UW Carbone Cancer Center Receives FDA Clearance to Test New Regenerative Medicine Therapy for Radiotherapy-Induced Dry Mouth
    UW Carbone Cancer Center Receives FDA Clearance to Test New Regenerative Medicine Therapy for Radiotherapy-Induced Dry MouthSeptember 8th, 2020
  • ONLINE: Taking down Cancer with Tech
    ONLINE: Taking down Cancer with TechAugust 18th, 2020
  • Tuskegee Nurse Who Faced Racism During WWII Is Helping Delaware Valley Kids
    Tuskegee Nurse Who Faced Racism During WWII Is Helping Delaware Valley KidsMarch 7th, 2020
  • Join now to see all

Grant Support

  • Phase 1 And Phase 2 Clinical Trials Of Cancer Chemoprevention AgentsNational Cancer Institute2011
  • Enhancing Bioavailability Of ResveratrolNational Cancer Institute2010–2011
  • Protocol SpecificNational Cancer Institute2007–2011
  • Program LeadersNational Cancer Institute2007–2011
  • Clinical Research Central OfficeNational Cancer Institute2007–2011
  • Phase 2B DFMO Chemoprevention Of Skin Cancers In Organ Transplant RecipientsNational Center For Research Resources2005–2007
  • Chemoprevention Of Skin Cancer: Difluoromethylornithine (DFMO) Phase III TrialNational Center For Research Resources2004–2005
  • Chemoprevention Of Skin Cancer - DFMO Phase III TrialNational Cancer Institute2004–2005
  • DFMO Prevention Study (2B) In Organ Transplant SubjectsNational Cancer Institute2002–2005
  • Chemoprevention Of Skin Cancer--Dfmo Phase 3 TrialNational Cancer Institute2001–2002
  • Phase II Study Of L PAM PLUS BSO In Patients W/ Metastatic MelanomaNational Center For Research Resources1999–2002
  • Phase I Evaliuation Of Intravenous Mgi114 In Patients With Advanced CancerNational Center For Research Resources1998–2002
  • Phase II Trial Of IV L-PAM And BSO In Relapsed Or Refractory Ovarian CancerNational Center For Research Resources1997–2002
  • Phase I Trial Of Perillyl Alcohol 4 Times /DayNational Center For Research Resources2000
  • Perillyl Alcohol (Nsc 641066) Daily In Metastatic Breast CancerNational Center For Research Resources2000
  • Phase II Trial Of IV L PAM &Bso In Relapse /Refractory Ovarian CancerNational Center For Research Resources1997–1999
  • Daily Perillyl Alcohol Therapy In Advanced Breast CancerNational Cancer Institute1997–1998
  • Glutathione Modulation In Ovarian Cancer TreatmentNational Cancer Institute1995–1998
  • Uwccc Clinical Investigator AwardNational Cancer Institute1993–1995

Professional Memberships

Hospital Affiliations